Midostaurin
Sign in to save this workspacePrimary targets: FLT3 · FDA status: FDA Approved
Selectivity scorecard
KISS
78.64
Gini
0.500
CATDS
0.006
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Midostaurin. Strongest target: JAK3 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | JAK3 | 100.0% | 0.0% |
| 2 | MST2_STK3 | 100.0% | 0.0% |
| 3 | PHKG1 | 100.0% | 0.0% |
| 4 | GLK_MAP4K3 | 99.4% | 0.6% |
| 5 | MLK3_MAP3K11 | 99.2% | 0.8% |
| 6 | CAMK2D | 98.9% | 1.1% |
| 7 | JAK2 | 98.9% | 1.1% |
| 8 | SIK2 | 98.8% | 1.2% |
| 9 | FLT3 | 98.6% | 1.4% |
| 10 | RSK3 | 98.5% | 1.5% |
| 11 | PKN1_PRK1 | 98.5% | 1.5% |
| 12 | AURORA_A | 98.4% | 1.6% |
| 13 | ARK5_NUAK1 | 98.3% | 1.7% |
| 14 | MLK1_MAP3K9 | 98.0% | 2.0% |
| 15 | YSK4_MAP3K19 | 97.9% | 2.1% |
| 16 | MARK4 | 97.9% | 2.1% |
| 17 | MST1_STK4 | 97.4% | 2.6% |
| 18 | MARK3 | 97.4% | 2.6% |
| 19 | AMPK(A1_B2_G2) | 97.3% | 2.7% |
| 20 | FMS | 97.3% | 2.7% |
Selectivity landscape
Where Midostaurin sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Midostaurin.
Annotations
Sign in to read and post annotations.
Loading…